About
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Current Value
$31.301 Year Return
Current Value
$31.301 Year Return
Key Details
Market Cap
$13.78B
P/E Ratio
16.58
1Y Stock Return
10.69%
1Y Revenue Growth
-3.85%
Dividend Yield
3.29%
Price to Book
2.0
Strategies that include RPRX
Double maintains 6 strategies that include RPRX - Royalty Pharma Plc
Founder Mode
High risk
$1,000
Stocks only get included in this basket, if the companies founders are still actively involved in the company. We equally weight them. Paul Graham talks a bit about Founder Mode in a recent 2024 essay.
Top Sector
Information Technology
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
92
Value Stocks
Medium risk
$6.8K
This Strategy targets undervalued stocks in the U.S. market, emphasizing companies with solid fundamentals and potential for long-term growth. Emphasizing sectors such as healthcare, financials, industrials, and consumer goods, it seeks opportunities where market prices may not fully reflect underlying value metrics like earnings and book value.
Top Sector
Financials
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
337
USA Mid-Cap Companies
Medium risk
$3.8K
Targeting mid-sized U.S. companies, striking a balance between growth potential and stability. Investing in sectors like industrials, technology, consumer goods, and healthcare, it offers exposure to companies with established market positions and growth opportunities.
Top Sector
Industrials
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
316
Health Care Sector
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
US 1000
Medium risk
$33.0K
This strategy tracks a market-cap-weighted index of the 1000-largest US companies. It offers broad exposure to the US equity market, encompassing a diverse range of sectors and industries. By investing in this fund, you gain access to the performance of large and well-established companies within the US economy.
Top Sector
Information Technology
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
1000
Stock's related to RPRX
The stocks that are correlated to RPRX - Royalty Pharma Plc are SW, AEP, WBA, SUNS, DAR
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 38.84% | $22.29B | -7.59% | 2.55% | |
| 36.75% | $58.26B | +29.95% | 3.31% | |
| 32.93% | $9.56B | -41.73% | 6.95% | |
| 32.57% | $141.87M | -6.46% | 8.88% | |
| 30.24% | $4.98B | -29.94% | 0.00% | |
N NTRNutrien Ltd. | 28.26% | $24.81B | -9.75% | 4.47% |
| 28.01% | $1.20B | +14.77% | 0.00% | |
D DTEDTE Energy Co. | 27.10% | $28.95B | +27.32% | 3.05% |
| 26.59% | $1.80B | -27.94% | 0.00% | |
| 26.41% | $30.56B | -0.25% | 4.57% | |
| 26.29% | $19.91B | -20.81% | 2.97% | |
| 26.21% | $22.43B | -11.68% | 0.87% | |
S SNXTD SYNNEX Corp. | 25.81% | $8.39B | -15.16% | 1.70% |
N NTSTNetSTREIT Corp. | 25.72% | $1.28B | -11.05% | 5.38% |
| 25.02% | $385.14B | +4.80% | 3.12% | |
G GSKGSK Plc | 24.89% | $79.34B | -4.53% | 4.12% |
O OGSONE Gas, Inc. | 24.85% | $4.57B | +19.18% | 3.50% |
| 24.81% | $22.84B | -24.78% | 4.47% | |
C CLVTClarivate Plc | 24.71% | $2.52B | -50.27% | 0.00% |
P PFEPfizer Inc. | 24.66% | $137.76B | -8.86% | 7.08% |
ETF's related to RPRX
The ETFs that are correlated to RPRX - Royalty Pharma Plc are CPRJ, MOO, IHE, GCOW, VEGI
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 42.50% | $48.65M | 0.69% | |
| 31.79% | $566.97M | 0.53% | |
| 29.36% | $623.79M | 0.39% | |
| 28.76% | $2.19B | 0.6% | |
| 26.82% | $87.96M | 0.39% | |
| 25.75% | $964.24M | 0.62% | |
| 25.51% | $814.02M | 0.53% | |
| 24.70% | $3.91B | 0.41% | |
| 24.66% | $453.03M | 0.68% | |
| 24.38% | $790.48M | 0.4% | |
| 24.15% | $158.44M | 0.35% | |
| 24.09% | $237.73M | 0.41% | |
| 23.91% | $6.17B | 0.42% | |
| 23.80% | $251.13M | 0.59% | |
| 23.53% | $920.92M | 0.08% | |
| 23.51% | $371.43M | 0.58% | |
| 23.40% | $16.30B | 0.09% | |
| 23.24% | $37.96B | 0.09% | |
| 23.17% | $352.92M | 0.5% | |
| 23.13% | $650.56M | 0.36% | |
News
Yahoo
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company’s plans to drive shareholder value creation through leveraging its unique business model and capabilities in the large and growing market for funding biopharma innovation. The meeting will include live question and answer se
Yahoo
We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look at where Royalty Pharma plc (NASDAQ:RPRX) stands against other best defensive stocks amid market volatility. With ongoing inflation, economic uncertainty, and global tensions, more investors are looking for ways to protect their […]
SeekingAlpha
Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.
SeekingAlpha
Read here for key dividend updates for Dividend Champions, Contenders, and Challengers. Learn about changes, ex-dividend dates, & payment schedules.
Yahoo
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical r
SeekingAlpha
Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new patients starts flat. Read more here.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds